Jiangsu HengRui Medicine Co., Ltd.: Carcinoma, Non-Small-Cell Lung trials

The registry lists 33 Carcinoma, Non-Small-Cell Lung studies with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor. 14 are open to participants now and 1 have results posted.

Phase 1 7Phase 2 20Phase 3 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overexpressing Non-squamous Non-small Cell Lung CancerNot yet recruitingNCT07896005Phase 3
• An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.Not yet recruitingNCT07863167Phase 2
• A Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung CancerRecruitingNCT07489716Phase 2
• A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung CancerRecruitingNCT07229729Phase 2
• Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer SubjectsRecruitingNCT07175220Phase 2
• Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT07170995Phase 3
• A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLCRecruitingNCT06754930Phase 1/2
• A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT06589778Phase 1/2
• A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung CancerRecruitingNCT06512051Phase 1/2
• A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC PatientsNot yet recruitingNCT06335355Phase 2/3
• Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung CancerNot yet recruitingNCT05503888Phase 1/2
• Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung CancerRecruitingNCT05416775Phase 1/2
• A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerRecruitingNCT05042375Phase 3
• A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLCRecruitingNCT04316364Phase 3
• A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)CompletedNCT03083041Phase 2Results posted
• A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLCActive, not recruitingNCT07183189Phase 3
• A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLCActive, not recruitingNCT06671379Phase 3
• To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLCCompletedNCT05169801Phase 3
• A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-CancerStatus unknownNCT05132413Phase 3
• Study of SHR-1701 Plus BP102 in Subjects With Selected Solid TumorsStatus unknownNCT04974957Phase 2
• A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04818333Phase 1/2
• A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLCWithdrawnNCT04699968Phase 2
• A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLCActive, not recruitingNCT04580498Phase 2
• Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04203485Phase 3
• A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLCStatus unknownNCT03904823Phase 2
• Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung CancerTerminatedNCT03777124Phase 2
• A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLCCompletedNCT03134872Phase 3
• A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLCStatus unknownNCT03085069Phase 2
• SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung CancerTerminatedNCT02766140Phase 3
• A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02364362Phase 1
• A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)SuspendedNCT02356991Phase 2
• Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)Status unknownNCT02332512Phase 3
• A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung CancerCompletedNCT01270386Phase 2